NCT Integrative Radiation Oncology Program
Treatment outcomes of radiation therapy critically depend on reaching the tumor tissue as completely as possible while sparing surrounding healthy tissue. The aim of the Program Area of Integrative Radiation Oncology (coordinator: Prof. Dr. Dr. Jürgen Debus) is to integrate the most advanced imaging technologies into radiation oncology.
This will make it possible to use simultaneous or real-time imaging to reach the tumor areas in the body very specifically and thus to carry out tissue-saving treatment tailored to the individual patient.
The program collaborates closely with Molecular Diagnostics to facilitate and accelerate clinical testing of new diagnostic methods in carefully planned clinical trials. The concept is to exploit all currently available molecular imaging possibilities for treatment planning and surveillance.
Collaborations with the Clinical Discovery Program are aimed at understanding the potential of different treatment combinations and testing new therapy approaches.
(1) a novel p16INK4a staining technique for HPV-related lesions (Reuschenbach Int J Cancer 2012; Ikenberg J Natl Cancer Inst. 2013). This CINtec plus test in global use was developed by mtm laboratories AG, acquired by Roche in 2011 (http://www.ventana.com/cervical). (2) familial risk of cancer (Kharazmi BMJ 2012), (3) TERT promoter mutations in sporadic melanoma (Horn Science 2013), (4) translocations may have a genetic basis (Weinhold Nature Genet 2013), (5) new genetic susceptibility loci for multiple myeloma (Chubb Nature Genet 2013), and (6) personalized prevention strategies based on inherited genetic characteristics (Coghill Gut 2011; Seufert Carcinogenesis 2013; Coghill Clin Canc Res 2011; Kraus Pharmacogen Genom 2013; Haug Genes Chrom Cancer 2012).